NO20071330L - Enzyminhibitor i leukemi - Google Patents

Enzyminhibitor i leukemi

Info

Publication number
NO20071330L
NO20071330L NO20071330A NO20071330A NO20071330L NO 20071330 L NO20071330 L NO 20071330L NO 20071330 A NO20071330 A NO 20071330A NO 20071330 A NO20071330 A NO 20071330A NO 20071330 L NO20071330 L NO 20071330L
Authority
NO
Norway
Prior art keywords
leukemia
enzyme inhibitor
treatment
aml
medicament
Prior art date
Application number
NO20071330A
Other languages
English (en)
Norwegian (no)
Inventor
Tsvee Lapidot
Sigal Tavor
Isabelle Petit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20071330L publication Critical patent/NO20071330L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20071330A 2004-08-10 2007-03-12 Enzyminhibitor i leukemi NO20071330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL163453A IL163453A0 (en) 2004-08-10 2004-08-10 Enzyme inhibitor in leukemia
PCT/IL2005/000840 WO2006016353A2 (en) 2004-08-10 2005-08-04 Elastase inhibitor in leukemia

Publications (1)

Publication Number Publication Date
NO20071330L true NO20071330L (no) 2007-03-12

Family

ID=35124397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071330A NO20071330L (no) 2004-08-10 2007-03-12 Enzyminhibitor i leukemi

Country Status (10)

Country Link
US (1) US20090232793A1 (de)
EP (1) EP1781377B1 (de)
JP (1) JP4950885B2 (de)
AT (1) ATE552888T1 (de)
AU (1) AU2005270821B2 (de)
CA (1) CA2576419C (de)
ES (1) ES2381195T3 (de)
IL (2) IL163453A0 (de)
NO (1) NO20071330L (de)
WO (1) WO2006016353A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
WO2017049002A1 (en) * 2015-09-15 2017-03-23 Massachusetts Institute Of Technology A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system
CN116087338B (zh) * 2023-04-10 2023-07-14 四川省地质矿产勘查开发局一0六地质队 一种岩石脆性破坏前兆指标的构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
EP0850252B1 (de) * 1996-04-12 2005-06-08 American National Red Cross Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen
US5760027A (en) * 1996-12-06 1998-06-02 Research Corporation Technologies, Inc. Use of 7-alkylidene cephalosporins to inhibit elastase activity
GB9719172D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
EP1390497A2 (de) * 2001-05-25 2004-02-25 Genset Menschliche cdns und proteine und verwendungen davon
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
AU2003299526A1 (en) * 2002-06-14 2004-06-07 North Shore - Long Island Jewish Research Institute Novel human elastases and stress urinary incontinence

Also Published As

Publication number Publication date
JP2008509903A (ja) 2008-04-03
US20090232793A1 (en) 2009-09-17
AU2005270821B2 (en) 2011-06-02
ES2381195T3 (es) 2012-05-24
CA2576419C (en) 2013-07-02
EP1781377A2 (de) 2007-05-09
EP1781377B1 (de) 2012-04-11
IL181183A (en) 2010-12-30
WO2006016353A3 (en) 2006-07-13
IL163453A0 (en) 2009-02-11
ATE552888T1 (de) 2012-04-15
IL181183A0 (en) 2007-07-04
AU2005270821A1 (en) 2006-02-16
JP4950885B2 (ja) 2012-06-13
CA2576419A1 (en) 2006-02-16
WO2006016353A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
PL1789390T3 (pl) Pirydylowe inhibitory szlaku sygnałowego hedgehog
HN2003000227A (es) Inhibidores de quinasas
EA200700717A1 (ru) Сульфонамиды
TW200510397A (en) Conjugated complement cascade inhibitors
ATE424159T1 (de) Katheter
DE602004010206D1 (de) Dipeptidyl Peptidase Inhibitoren.
NO20053041D0 (no) Behandling av diabetes.
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ATE486297T1 (de) Mehrstufige schicht
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
BRPI0511615A (pt) forma de administração oral compreendendo bactéria probiótica
MX2009002960A (es) Inhibidores de serina hidrolasa.
CR7758S (es) Barra de caramelo (paloma)
MX2007007613A (es) Formulaciones farmaceuticas.
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
SE0302304D0 (sv) Novel compounds
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
NO20071330L (no) Enzyminhibitor i leukemi
NO20072190L (no) Fremgangsmater og sammensetninger for behandling av kronisk lymfatisk leukemi
DE50309647D1 (de) Ng fibrotischer erkrankungen
NO20055582L (no) Preparater og fremgangsmater omfattende gastrinforbindelser
ATE484195T1 (de) Gewebe-engineering
AU2003222462A1 (en) Method of performing soojichim acupuncture using bodycopy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application